More than 750 patents
ROVI has a well-protected portfolio composed of 750 patent dossiers, 623 of which have already been granted, while 128 are in the examination and evaluation phase.
623 granted patents
128 in examination
and evaluation phase
During 2024, we invested €25.8 million in R&D, 3% more than in 2023.
The success of
Bemiparin®
Our innovation and development policy is reflected in the success of Bemiparin, the first second-generation, low-molecular-weight heparin, which has become the Company’s main product and is currently marketed in more than 55 countries.
BEMIPARIN®
Treatment of established deep vein thrombosis, with or without pulmonary embolism
Our R&D investment
During 2024, we invested €25.8 million in R&D, 3% more than in 2023.
R&D projects
Proyecto LAISOLID - IPCEI MED4CURE
LAISOLID is a R&D project associated to the IPCEI project Medi4Cure Health, focused on developing new sterile filling technologies for polymeric matrices and new methodologies to accelerate the development of medicines based on predictive models.
ROVI intends to provide technological solutions that can be applied in tissue regeneration and in the development of pharmacological treatments that enhance efficacy in therapies for serious pathologies like breast cancer.
The project submitted proposes also a new approach to the development of medicines based on predictive models that will accelerate the development of new pharmacological treatments with improved efficacy through the development and validation of models that establish quantitative relationships between formulation parameters and their clinical efficacy.
The project is funded by the CDTI and falls within the Recovery, Transformation and Resilience Plan financed under the European Union Recovery and Resilience Facility.
ISM
The ISM® platform allows the sustained release of compounds administered by injection and has the advantage of reducing variability, improving stability and minimizing the number of doses necessary, thus improving the degree of patent adherence to the prescribed treatment.
Glycomics
Glycomics is the study and profiling of the sugars that compose a cell, including the glycosaminoglycans (GAG), which, in addition to their role in regulating blood coagulation, are involved in processes like cell growth, immune response and inflammation.
Multilayer technologies for urethral catheters
One of the most important aspects in the use of stents and urethral catheters is the high prevalence of bacteria that, in some cases, may lead to the appearance of clinical symptoms and complications, including severe sepsis and death.